Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Germany Could Introduce Biosimilar Substitution By Pharmacists In Three Years

A German bill aims to cut spending on biologics, but new revisions mean that measures on biosimilar substitution are likely to be delayed by three years.

Europe Germany

Germany To Increase Data Requirements For Pricing Orphan And Other Drugs

A new bill going through the German legislative process could oblige manufacturers of orphan drugs and certain other products to submit real-world data from registries that would impact pricing.

Europe Germany

Collaboration And Pay For Performance Deals – The Way To Pay for One-Off Treatments

New payment models, registries and the Cross Border Healthcare Directive could help determine new ways to pay for potentially one-off treatments such as gene therapies in Europe.

Europe Government Payers

Mixed HTA Results As Scotland Says No To Yescarta But Yes To Kymriah

The Scottish Medicines Consortium has recommended one CAR-T therapy, Novartis’ Kymriah, for use on Scotland’s National Health Service but rejected another, Gilead’s Yescarta, claiming the company has failed to prove it would be cost-effective.

Europe United Kingdom

England And Canada Collaborate On Parallel Scientific Advice For HTA

Health technology appraisal institutes in England and Canada are joining forces to offer parallel scientific advice and both agencies say they are open to more international collaborations.

Europe United Kingdom

International HTA Agencies Collaborate On How To Determine Value-Based Prices

Health technology assessment agencies in the US, the UK and Canada are working together to develop new ways of determining value-based prices for potentially curative treatments like gene therapies.

Europe United Kingdom
See All
Advertisement
UsernamePublicRestriction

Register